Cargando…

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo

Adoptive T-cell therapy with gene-modified T-cells expressing a tumor-reactive T-cell receptor (TCR) or chimeric antigen receptor (CAR) is a rapidly growing field of translational medicine and has shown success in the treatment of B-cell malignancies and solid tumors. In all reported trials, patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommermeyer, Daniel, Hudecek, Michael, Kosasih, Paula L., Gogishvili, Tea, Maloney, David G., Turtle, Cameron J., Riddell, Stanley R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746098/ https://www.ncbi.nlm.nih.gov/pubmed/26369987 http://dx.doi.org/10.1038/leu.2015.247

Ejemplares similares

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy
por: Liu, Lingfeng, et al.
Publicado: (2016)

Murine CD4+ T cell subsets defined
Publicado: (1988)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Human Liver Macrophage Subsets Defined by CD32
por: Wu, Xia, et al.
Publicado: (2020)

Changes in Reactivity In Vitro of CD4(+)CD25(+) and CD4(+)CD25(−) T Cell Subsets in Transplant Tolerance
por: Hall, Bruce M., et al.
Publicado: (2017)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

CD161 expression defines new human γδ T cell subsets
por: Karunathilaka, Amali, et al.
Publicado: (2022)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity
por: Lindau, Paul, et al.
Publicado: (2019)

CXCR5(+)CD8(+) T cells are a distinct functional subset with antitumor activity
por: Chu, Fuliang, et al.
Publicado: (2019)

Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19(+) Tumor Cells
por: Lin, Zhicai, et al.
Publicado: (2022)

Characterization of Human CD8(+) T Cells Reactive with Mycobacterium tuberculosis–infected Antigen-presenting Cells
por: Lewinsohn, David M., et al.
Publicado: (1998)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Normally occurring NKG2D(+)CD4(+) T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus
por: Dai, Zhenpeng, et al.
Publicado: (2009)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
por: Mancikova, Veronika, et al.
Publicado: (2020)

CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation
por: Hünig, Thomas, et al.
Publicado: (2010)

CD4(+)CD25(+)CD127(−) and CD4(+)CD25(+)Foxp3(+) Regulatory T Cell Subsets in Mediating Autoimmune Reactivity in Systemic Lupus Erythematosus Patients
por: Żabińska, Marcelina, et al.
Publicado: (2016)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33(+) Acute Myeloid Leukemia
por: Dutour, A., et al.
Publicado: (2012)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

CD160 and PD-1 Co-Expression on HIV-Specific CD8 T Cells Defines a Subset with Advanced Dysfunction
por: Peretz, Yoav, et al.
Publicado: (2012)

Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma
por: Wu, Hongyan, et al.
Publicado: (2021)

Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens
por: White, Matthew J, et al.
Publicado: (2014)

Superior antigen cross-presentation and XCR1 expression define human CD11c(+)CD141(+) cells as homologues of mouse CD8(+) dendritic cells
por: Bachem, Annabell, et al.
Publicado: (2010)

CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo
por: Tang, Xiaojun, et al.
Publicado: (2019)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
por: Gogishvili, Tea, et al.
Publicado: (2009)

Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
por: Zhou, Jianxia, et al.
Publicado: (2019)

CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells
por: Kurioka, Ayako, et al.
Publicado: (2018)

The CD14(+/low)CD16(+) monocyte subset is more susceptible to spontaneous and oxidant-induced apoptosis than the CD14(+)CD16(−) subset
por: Zhao, C, et al.
Publicado: (2010)

Restoration of CD28 Expression in CD28(−) CD8(+) Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production
por: Topp, Max S., et al.
Publicado: (2003)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

Distinctive CD26 Expression on CD4 T-Cell Subsets
por: Cordero, Oscar J., et al.
Publicado: (2021)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2015)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
por: Alvarez‐Fernández, Carmen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rsuri92ul9h2p4mnbfr1r853jg